Advertisement

17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very Worried

17 Reasons to Be Excited About Sorrento Therapeutics and 1 Big Reason to Be Very Worried

At the beginning of this year, Sorrento Therapeutics (NASDAQ: SRNE) was focused on its pain management drug, resiniferatoxin, as well as its Dimeric Antigen Receptor-T (DAR-T) cell therapy targeting various blood cancers and solid tumors. Disclosing that it had developed STI-4398, a protein designed to bind and neutralize the novel coronavirus. Collaborating with SmartPharm Therapeutics to develop an antibody vaccine for COVID-19.